Primary hyperparathyroidism is a hormone disorder in which one or more parathyroid glands release too much parathyroid hormone, or PTH. The parathyroid glands sit near the thyroid but perform a different job: they help regulate calcium through effects on the bones, kidneys, and intestines. When PTH remains too active, blood calcium can rise while bone mineral is gradually lost and kidney-stone risk may increase.
Many people first encounter this issue when a routine comprehensive metabolic panel shows high calcium. The key is not to view calcium as an isolated number. Calcium, albumin, PTH, vitamin D status, kidney function, medications, and the pattern over time all help determine whether the parathyroid glands are responding normally.
Ulta Lab Tests provides access to many relevant blood and urine tests online where available, which can make confirmation and trend monitoring more convenient. Lab testing provides objective information, but it does not replace a clinician’s diagnosis, imaging, bone-density testing, treatment plan, or medical judgment.
Answer in brief: Primary hyperparathyroidism begins in the parathyroid glands. One or more glands make excess PTH, causing calcium to rise or remain higher than it should be.
PTH acts as the body’s calcium regulator. When calcium falls, normal parathyroid glands release PTH to bring it back up. PTH can increase calcium by encouraging release from bone, supporting intestinal calcium absorption through vitamin D pathways, and changing how the kidneys handle calcium and phosphorus.
In primary hyperparathyroidism, this feedback system is disrupted. The most common cause is a benign parathyroid adenoma, a noncancerous growth in one gland. Less often, multiple glands are enlarged or overactive. Parathyroid cancer is rare. NIDDK reports that about eight in ten cases involve a single benign adenoma.
The condition most often affects adults in midlife and later life and is more common in women, although it can occur at any age. Younger age, multigland disease, lifelong high calcium, or a family history can raise concern for an inherited form.
Symptoms alone cannot confirm the condition. Many people have no noticeable symptoms, while fatigue, constipation, weakness, low mood, poor concentration, thirst, and frequent urination can occur in many other health problems. The calcium-PTH relationship provides more specific information than symptoms alone.
Answer in brief: Persistently excessive PTH can affect the skeleton and kidneys even when a person feels well.
High PTH can increase the movement of calcium out of bone. Over time, this may contribute to osteopenia, osteoporosis, or fragility fractures. Bone loss can occur at the lumbar spine, hip, and distal one-third radius, which is why guideline-based evaluation uses a three-site DXA rather than relying on a single location.
Extra calcium filtered through the kidneys may contribute to kidney stones. Primary hyperparathyroidism can also be associated with nephrocalcinosis, meaning calcium deposits in kidney tissue, and with reduced kidney function. A person can have a silent stone or reduced bone density without obvious symptoms.
More marked hypercalcemia may cause nausea, vomiting, constipation, poor appetite, dehydration, excessive thirst, frequent urination, confusion, and pronounced muscle weakness. These symptoms are not unique to parathyroid disease, but they become more concerning when paired with a clearly high calcium result.
Research continues into possible cardiovascular, quality-of-life, and neurocognitive effects. Current international guidance does not recommend using nonspecific cardiovascular or cognitive findings alone as reasons for parathyroid surgery because the evidence remains inconclusive.
| Symptom or risk factor | What it may suggest | Tests that may provide more information |
|---|---|---|
| Repeated high calcium on a CMP | Persistent hypercalcemia that needs confirmation and PTH interpretation | Comprehensive Metabolic Panel Test - CMP , Calcium Test , Albumin Test , PTH Intact Test , and Renal Function Panel Test |
| Kidney stones, flank pain, or blood in urine | Increased urinary calcium or another stone-risk disorder | Renal Function Panel Test , Urinalysis Complete Test , and Calcium 24 Hour Urine Test with Creatinine ; kidney imaging when indicated |
| Osteopenia, osteoporosis, height loss, or low-trauma fracture | Possible skeletal effects of excess PTH or another bone disorder | Calcium Test , PTH Intact Test , Vitamin D 25-Hydroxy Total Immunoassay Test , and Alkaline Phosphatase Test ; three-site DXA and vertebral imaging when indicated |
| Fatigue, weakness, constipation, thirst, or frequent urination | Possible hypercalcemia, but also many unrelated conditions | Comprehensive Metabolic Panel Test - CMP , Calcium Test , Albumin Test , PTH Intact Test , Phosphate (as Phosphorus) Test , and Magnesium Test , plus symptom-directed testing |
| High PTH with normal calcium | Often secondary hyperparathyroidism; the normocalcemic form requires careful exclusion | Repeat Calcium Test and Calcium Ionized Test , plus Vitamin D 25-Hydroxy Total Immunoassay Test , Renal Function Panel Test , Phosphate (as Phosphorus) Test , and malabsorption testing when indicated |
| Lifelong high calcium, low urine calcium, young age, or family history | Familial hypocalciuric hypercalcemia or another inherited condition | Calcium 24 Hour Urine Test with Creatinine , clearance-ratio review, and possible genetic evaluation |
Safety note: Seek prompt medical care for new confusion, fainting, repeated vomiting, inability to stay hydrated, severe weakness, or significant palpitations. Do not wait for routine repeat testing when symptoms are severe or rapidly worsening.
Answer in brief: Testing may be reasonable after repeated high calcium, kidney stones, unexplained bone loss or fracture, high PTH, reduced kidney function, or symptoms that occur alongside an abnormal calcium result.
Consider discussing a focused calcium-PTH evaluation with a healthcare professional when:
Testing should be targeted rather than broad. Cardiometabolic markers such as the A1c Test and Lipid Panel Test , sex hormones, or autoimmune panels may be useful for separate health questions, but they do not establish primary hyperparathyroidism.
Lab testing helps confirm that calcium is persistently high, determines whether PTH is appropriately suppressed, checks vitamin D and kidney function, and guides urine-calcium assessment. Trends are often more informative than a single result because hydration, albumin, medications, supplements, illness, and laboratory variation can affect values.
Blood and urine tests cannot measure bone density, identify every kidney stone, or locate an abnormal gland. DXA and kidney imaging may be needed. Neck ultrasound, sestamibi scanning, and other localization studies are for surgical planning after the biochemical diagnosis is established, not for initial screening.
| Laboratory pattern | General interpretation | Important next considerations |
|---|---|---|
| High calcium with high or inappropriately normal PTH | Parathyroid-dependent hypercalcemia; classic pattern of primary hyperparathyroidism | Confirm on repeat testing with albumin; assess vitamin D, kidney function, urine calcium, bones, and kidneys |
| High calcium with suppressed PTH | Points away from primary hyperparathyroidism | Clinician-directed evaluation for non-parathyroid causes such as malignancy-related hypercalcemia, excess vitamin D activity, granulomatous disease, or medication effects |
| High PTH with normal calcium | Often a secondary response rather than primary disease | Exclude vitamin D deficiency, chronic kidney disease, low calcium intake, malabsorption, bariatric surgery, and medication effects; repeat total and ionized calcium |
| High calcium with unexpectedly low urine calcium | May suggest familial hypocalciuric hypercalcemia | Review 24-hour collection quality, kidney function, vitamin D, thiazide or lithium use; consider clearance-ratio and genetic evaluation |
Normocalcemic primary hyperparathyroidism is a diagnosis of exclusion. The Fifth International Workshop describes it as normal adjusted total and ionized calcium with elevated PTH on at least two occasions over three to six months, after alternative causes of secondary hyperparathyroidism have been ruled out.
| Lab test or biomarker | What it measures and why it matters | General result pattern | Important limitations and relevant Ulta Lab Tests option |
|---|---|---|---|
| Calcium Test and Albumin Test | Calcium is often the first clue; albumin helps interpret protein-bound calcium. | Persistent high calcium supports hypercalcemia, but dehydration, medications, and non-parathyroid causes remain possible. | Interpret together and repeat when appropriate. See the Comprehensive Metabolic Panel Test - CMP . |
| PTH Intact Test | Shows whether the parathyroid response matches the calcium level. | High or nonsuppressed PTH with high calcium supports a parathyroid-driven pattern; high PTH with normal or low calcium often reflects a secondary cause. | Must be read with calcium, vitamin D, and kidney function; biotin may interfere with some assays. See the PTH Intact Test . |
| Calcium Ionized Test or PTH Intact Test with Ionized Calcium | Measures unbound, biologically active calcium. | High ionized calcium supports true hypercalcemia and can clarify a discordant total-calcium result. | Handling and pH affect the specimen; it is not needed in every case. See the Calcium Ionized Test or PTH Intact Test with Ionized Calcium . |
| Phosphate (as Phosphorus) Test and Vitamin D 25-Hydroxy Total Immunoassay Test | Phosphorus reflects PTH and kidney handling; 25-hydroxyvitamin D assesses vitamin D status. | Phosphorus may be low or low-normal in primary disease. Low vitamin D can raise PTH and mimic or worsen a secondary pattern. | Neither result diagnoses the condition alone. See the Phosphate (as Phosphorus) Test and Vitamin D 25-Hydroxy Total Immunoassay Test . |
| Creatinine Test and Renal Function Panel Test | Estimate kidney filtration and help identify kidney-related secondary hyperparathyroidism or renal involvement. | Reduced eGFR may raise PTH and is also a marker of kidney complications. | eGFR varies with age, muscle mass, hydration, and method. Included in the CMP and Renal Function Panel Test . |
| Magnesium Test and Alkaline Phosphatase Test | Magnesium participates in calcium-PTH regulation; alkaline phosphatase can reflect bone or liver activity. | Abnormal magnesium may complicate interpretation; high alkaline phosphatase may reflect bone turnover or liver/biliary disease. | Neither is specific. See the Magnesium Test and Alkaline Phosphatase Test . |
| Calcium 24 Hour Urine Test with Creatinine | Assesses daily calcium excretion, collection completeness, stone risk, and possible FHH. | High urine calcium may indicate hypercalciuria; very low calcium relative to creatinine may favor FHH. | Incomplete collection, kidney disease, vitamin D deficiency, thiazides, and lithium can distort results. See the Calcium 24 Hour Urine Test with Creatinine . |
A complete assessment may require:
Direct-access laboratory testing can reveal the biochemical signal, but it cannot replace these imaging and bone-density studies.
A focused first step commonly includes the Calcium Test , Albumin Test , PTH Intact Test drawn at the same time, Renal Function Panel Test , Phosphate (as Phosphorus) Test , and Vitamin D 25-Hydroxy Total Immunoassay Test . This confirms the calcium-PTH relationship and checks two common confounders: vitamin D deficiency and impaired kidney function.
Calcium Ionized Test may help when total calcium and the clinical picture do not agree or when normocalcemic primary hyperparathyroidism is being considered. Depending on history, additional testing may include the Magnesium Test , Alkaline Phosphatase Test , Calcium 24 Hour Urine Test with Creatinine , celiac or other malabsorption testing, and genetic evaluation for people younger than 30, multigland disease, lifelong hypercalcemia, or a family or syndromic history.
Once the biochemical pattern is established, evaluation may include three-site DXA, vertebral assessment, kidney imaging, and stone-risk testing. For people monitored without surgery, the Fifth International Workshop recommends clinician-supervised annual Calcium Test , Vitamin D 25-Hydroxy Total Immunoassay Test , and Renal Function Panel Test ; PTH Intact Test when indicated; and DXA every one to two years unless a longer interval is appropriate.
Answer in brief: Interpret calcium and PTH together, not as separate “normal” or “abnormal” flags.
Reference ranges vary by assay, units, and population. A slightly abnormal value does not prove disease, while a PTH marked “normal” does not rule out primary hyperparathyroidism when calcium is high because normal physiology should suppress PTH.
Albumin can change total-calcium interpretation, and ionized calcium may help when albumin is abnormal or the result does not fit the clinical picture. Hydration, pregnancy, kidney function, recent illness, medications, supplements, timing, and laboratory methodology can also affect results.
Thiazides and lithium can alter calcium-PTH patterns. Calcium, vitamin D, calcium-containing antacids, bisphosphonates, and denosumab may complicate interpretation. Biotin can produce a falsely low PTH result in some assays; the Fifth International Workshop notes that a 48-hour pause has been suggested. Follow test-specific instructions and do not stop prescribed medicine without guidance.
The guideline defines hypercalcemic primary hyperparathyroidism using elevated albumin-adjusted calcium with elevated or inappropriately normal intact PTH on two occasions at least two weeks apart. For established disease, it recommends maintaining 25-hydroxyvitamin D above 30 ng/mL and below the laboratory upper limit through cautious, clinician-guided supplementation.
Parathyroidectomy is the definitive treatment. The decision is individualized with a qualified clinician and, when appropriate, an experienced parathyroid surgeon.
The Fifth International Workshop recommends surgery for symptomatic disease and advises discussion when any one of these findings is present in otherwise asymptomatic disease:
These criteria guide a clinical discussion, not self-diagnosis. Preoperative imaging locates abnormal glands after biochemical confirmation; a negative scan does not exclude the condition.
Ulta Lab Tests allows consumers to order many relevant blood and urine tests online where available. Testing is performed through established laboratory networks such as Quest Diagnostics where applicable. Pricing is shown before ordering, insurance is not required, HSA or FSA payment may be available for eligible purchases, and results are delivered through a secure online account.
Direct access can make confirmation and trend review more convenient, but Ulta Lab Tests does not diagnose primary hyperparathyroidism, determine whether surgery is needed, or replace imaging, DXA, or professional medical care.
The core tests are the Calcium Test , Albumin Test , and PTH Intact Test measured together. The Comprehensive Metabolic Panel Test - CMP also provides kidney markers. The Phosphate (as Phosphorus) Test and Vitamin D 25-Hydroxy Total Immunoassay Test help clarify mineral balance and secondary causes. The Calcium Ionized Test may help when total calcium is difficult to interpret or the normocalcemic form is being considered.
Yes. When calcium is high, normal parathyroid glands should reduce PTH. A value inside the laboratory range may therefore be “inappropriately normal” if it is not suppressed. Calcium and PTH must be interpreted together rather than treating each reference-range flag as a separate answer.
The Fifth International Workshop defines hypercalcemic primary hyperparathyroidism using elevated albumin-adjusted calcium plus elevated or inappropriately normal intact PTH on two occasions at least two weeks apart. Timing may differ when calcium is markedly high, symptoms are concerning, or medication and hydration effects must be addressed.
It is often secondary hyperparathyroidism from vitamin D deficiency, chronic kidney disease, low calcium intake, malabsorption, bariatric surgery, or medication effects. Normocalcemic primary hyperparathyroidism is considered only after total and ionized calcium remain normal, PTH stays elevated, and these alternatives have been excluded.
Low vitamin D can stimulate extra PTH production and confuse interpretation. It also matters for bone health. In established primary hyperparathyroidism, supplementation should be individualized and monitored rather than used in large, unsupervised doses to correct the calcium-PTH pattern.
Unexpectedly low urine calcium may suggest familial hypocalciuric hypercalcemia, especially with lifelong mild hypercalcemia or family history. Kidney disease, vitamin D deficiency, thiazides, lithium, and incomplete collection can also lower it, so a clearance ratio and sometimes genetic evaluation are needed.
They can show kidney filtration, urinary calcium, and mineral patterns, but they cannot fully assess target-organ damage. DXA measures bone density, vertebral imaging can identify fractures, and kidney imaging can detect stones or nephrocalcinosis. These studies may be needed even without symptoms.
Many calcium and PTH tests do not require fasting, but instructions vary by laboratory and panel. Ulta Lab Tests offers many relevant tests for direct online ordering where available. Follow the exact preparation instructions and review results with a qualified healthcare provider.
New confusion, fainting, repeated vomiting, inability to hydrate, severe weakness, or significant rhythm symptoms require prompt medical assessment. Repeat testing is often useful for mild or unclear abnormalities, but a markedly high result or concerning symptoms should not be managed through routine self-directed retesting alone.
Primary hyperparathyroidism is a hormone pattern, not a single abnormal number. Persistent high calcium with PTH that is elevated or insufficiently suppressed can point to a parathyroid-driven process, while vitamin D, kidney function, medications, urine calcium, and family history help distinguish look-alike conditions.
Explore parathyroid hormone and calcium tests through UltaLabTests.com , and review results with a qualified healthcare provider who can integrate laboratory data with symptoms, medications, DXA, and imaging.
Explore Parathyroid and Calcium Tests
Primary hyperparathyroidism is a disorder in which one or more parathyroid glands release excess PTH, often causing blood calcium to rise. The most informative clue is high calcium paired with PTH that is elevated or not appropriately suppressed.
Related lab tests: Calcium Test , Albumin Test , Comprehensive Metabolic Panel Test - CMP , PTH Intact Test , Calcium Ionized Test , Phosphate (as Phosphorus) Test , Vitamin D 25-Hydroxy Total Immunoassay Test , Renal Function Panel Test , Magnesium Test , Alkaline Phosphatase Test , and Calcium 24 Hour Urine Test with Creatinine .
Ulta Lab Tests helps patients access many of these tests online where available, with transparent ordering and secure online results for informed provider discussions.
Disclaimer: Lab testing is informational and should be interpreted with a qualified healthcare provider; it does not replace diagnosis, imaging, or treatment planning.
These tests form the article’s central laboratory cluster because calcium, albumin, and intact PTH are interpreted together, while ionized calcium may provide additional information when total calcium and the broader clinical pattern do not agree.
These markers help provide context about vitamin D status, phosphorus balance, magnesium, and possible bone-related effects; they do not establish primary hyperparathyroidism by themselves.
These tests support assessment of kidney function, urinary calcium, and related kidney-stone risk. The calcium-to-creatinine clearance ratio discussed in the article is a calculated relationship rather than a separate product link.
These tests are included for broader cardiometabolic context. They do not diagnose primary hyperparathyroidism and should not be presented as part of the core calcium–PTH diagnostic pattern.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
